Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000935836-25-000528
Filing Date
2025-08-14
Accepted
2025-08-14 14:24:39
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 13494
2 AGREEMENT REGARDING JOINT FILING logosex99mf.htm EX-99 4948
  Complete submission text file 0000935836-25-000528.txt   20227
Mailing Address 300 FIFTH AVENUE WALTHAM MA 02451
Business Address 300 FIFTH AVENUE WALTHAM MA 02451 617-430-5595
CRESCENT BIOPHARMA, INC. (Subject) CIK: 0001253689 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-87811 | Film No.: 251217515
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 1 LETTERMAN DRIVE BLDG C, SUITE C3-350 SAN FRANCISCO CA 94129
Business Address 1 LETTERMAN DRIVE BLDG C, SUITE C3-350 SAN FRANCISCO CA 94129 4158014660
Logos Global Management LP (Filed by) CIK: 0001792126 (see all company filings)

EIN.: 833997742 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A